Sign in or Register

Already a member?

Sign in

Or sign in with your account on:

Not a member yet?


Pfizer Tops Estimates in Second Quarter, Reiterates Full Year Outlook

By  +Follow July 30, 2013 8:52AM
Tickers Mentioned:

Pfizer Inc. (PFE) , the biggest drugmaker in the world, on Tuesday reported second-quarter earnings that nipped past analyst predictions as the company fought through declining sales that were hamstringed by the loss of exclusivity on the blockbuster cholesterol fighter Lipitor.

For the quarter, NYC-based Pfizer said it generated $12.97 billion in revenue, compared to $13.97 billion in the second quarter last year.  Net income soared to $14.1 billion, or $1.98 per share, versus $3.25 billion, or 43 cents per share, in last year’s quarter.  In February, Pfizer spun-out its animal health business into a new company called Zoetis, Inc. (ZTS) .  In December 2012, it sold its nutrition business to Nestle SA ($NSRGY) for $11.85 billion, accounting for most of the surge in reported income.  Excluding gains from the sale, restructuring costs and other special items, adjusted profits for the second quarter totaled $4.0 billion, or 56 cents per share, compared to $4.45 billion, or 59 cents per share, in the year prior quarter.

Wall Street was expecting EPS of 55 cents on revenue of $13.01 billion.

Sales of Lipitor sank 55 percent from $1.22 billion in the second quarter of 2012 to $545 million in the latest quarter.  Sales of pneumococcal vaccine Prevnar slipped 3 percent to $969 million due to changes in government purchasing patterns.  Counterbalancing those losses, sales of Pfizer’s biggest drug Lyrica, which is indicated for fibromyalgia, diabetic nerve pain and more, improved by 10 percent to $1.13 billion.

Revenue for Pfizer’s leading business units – primary care, specialty care, emerging markets and established products – all declined compared to the year prior quarter.  Ian Read, chairman and chief executive at Pfizer, said in today’s statement that he expects emerging market business growth to accelerate in the second of the year, led by China.

“From a total company view, we are tracking to our expectations for the full year and continue to capitalize on the investments we are making to better position Pfizer for long-term success,” added Read.

The company backed its 2013 forecast of adjusted earnings in the range of $2.10 to $2.20 per share.

Sales of anti-cancer drugs rose 24 percent to $399 million, boosted in part by a 191-percent climb in sales of Xalkori to $67 million and $17 million in sales from new drug Inlyta.

Operating margin improved significantly from 29.9 percent to 41.3 percent.

Marking “the next step in Pfizer’s journey to further revitalize [its] innovative core,” Pfizer said on Monday that it intends to split its company into three new units.  One unit will focus on drugs that are patent-protected beyond 2015.  The second will include vaccines, oncology and consumer healthcare products.  The third will include drugs that have lost – or will soon lose – patent exclusivity, generics and future product collaborations.  The changes are slated to start happening in January.

Two new drugs, blood thinner Eliquis and rheumatoid arthritis drug Xeljanz, are thought by many to have the capabilities to grow into blockbusters, although Zeljanz is facing some hurdles in Europe with negative opinions being offered by a European Medicines Agency committee.  Zeljanz generated $33 million in sales in the second quarter. The FDA is reviewing a supplemental New Drug Application (NDA) for Zeljanz with a decision expected by February.  Topline results are expected from two ongoing phase 3 trials evaluating Zeljanz in the second quarter next year.  The FDA is also reviewing a supplemental NDA for Eliquis, with a decision expected by March 15, 2014. 

During the second quarter, Pfizer repurchased $3.3 billion worth of its common stock, bringing its first-half total to $8.7 billion.

Shares of PFE have risen 20 percent so far in 2013 through Monday’s close at $29.54.  

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions.

Liked What You Read? Join Equities.com and Connect With Your Favorite Financial Experts FOR FREE! Members of Equities.com gain access to our leading financial news and content, active social investment community, proprietary research tools including the 2014 Small-Cap Stars, E.V.A. reports and more.

Results for PFE
31 Oct 14 08:37:17
@simbatrading $GENE it sure does, + they suing $GSK $PFE as well
Value Line
31 Oct 14 08:34:10
Using a Value Line page helps investors weigh the investment prospects of pharma giants Merck and Pfizer. $MRK $PFE http://t.co/kEsqO4FnsO
Can Demiryürek
31 Oct 14 08:32:15
$PFE Go go go
FinSentS SP500
31 Oct 14 08:24:07
$PFE:US Traders Sell Pfizer on Strength on Insider Selling (PFE) #PFIZER INC http://t.co/TYwfdFtVx9 #SP500
31 Oct 14 07:35:04
Pfizer : CONTRACT AWARD - 65-- Pfizer, Inc. 65IB Drugs, Pharmaceuticals and Hematology related products Con... http://t.co/Swkq9VMUXQ $PFE
31 Oct 14 07:30:33
Trending #Biotech topics include $PFE, $CVS, #Halloween #stocks #invest See more http://t.co/0Uk8oXnazd
Offer U Can´t Refuse
31 Oct 14 06:50:32
Johnny Bleiss
31 Oct 14 06:40:12
Healthcare Multiples http://t.co/milT0A68Zi $XLV $VHT $IYH $JNJ $PFE $MRK $GILD $AMGN $ABBV $BMY $UNH $BIIB $CELG http://t.co/LuSFiGbnch
Alexander Morris
31 Oct 14 06:38:10
$PFE: At/Below 200DaySMA[-30.14]:28d, cl:+6, 4NearHi:BrkPLo+PHi[+142.7%], PrvCHi, tf:1001111, ch:+1.0%, goPop+[+0.6%], BigFlt:6.3B
31 Oct 14 06:32:10
$PFE's Trunemba Meningitis B vaccine received FDA approval on 10/29 on Ph2 results- $HALO PegpH20 will also when Ph2 duplicates Ph1b results
G Bend
31 Oct 14 06:21:08
RT @FiercePharma: Top-read in Fierce #Vaccines Thursday: Pfizer beats out Novartis with FDA MenB nod http://t.co/L8J3fIyOtr $PFE $NVS #phar…
average guy
31 Oct 14 05:47:49
RT @FiercePharma: Top-read in Fierce #Vaccines Thursday: Pfizer beats out Novartis with FDA MenB nod http://t.co/L8J3fIyOtr $PFE $NVS #phar…
31 Oct 14 05:37:22
Morningstar Gives “AA” Credit Rating to Pfizer $PFE http://t.co/q1yHcMvPze
Harry Walkman
31 Oct 14 05:31:03
$PFE Pfizer beats sales and profit forecasts, mum on future deals http://t.co/ONbeMk3GWq
Thomas Collins
31 Oct 14 05:31:02
$PFE Pfizer Inc.'s Earnings: Emerging Market Growth and Patent Expirations Square Off http://t.co/gukzqjsita
Andri Kusandri
31 Oct 14 05:28:55
RT @FiercePharma: Top-read in Fierce #Vaccines Thursday: Pfizer beats out Novartis with FDA MenB nod http://t.co/L8J3fIyOtr $PFE $NVS #phar…
Carly Helfand
31 Oct 14 05:28:31
Top-read in Fierce #Vaccines Thursday: Pfizer beats out Novartis with FDA MenB nod http://t.co/R7KPmd0BY0 $PFE $NVS #pharma
31 Oct 14 05:28:31
Top-read in Fierce #Vaccines Thursday: Pfizer beats out Novartis with FDA MenB nod http://t.co/L8J3fIyOtr $PFE $NVS #pharma
31 Oct 14 05:25:10
Pfizer : Pain Therapeutics Reports Q3 2014 Financial Results http://t.co/t1CigztRAz $PFE
POZ Magazine
31 Oct 14 04:25:18
GlaxoSmithKline Eyes an IPO for HIV-Focused ViiV Healthcare $GSK @ViiVUS $PFE $TYO http://t.co/zFZXdtpLYG
31 Oct 14 03:30:04
Insiders Selling: $SWFT $INFA $CAKE $EGHT $TRMB $BA $PFE $ABT $VVTV $NBIX $SNA $FAF $HA $SAVE $MET http://t.co/Vv2VEn80mr #investing #stock
31 Oct 14 03:01:39
Weekly S&P100 #Stocks Trend $BMY $MA $V $AMGN $GILD $AEP $EXC $MET $LMT $PG $RTN $PFE $JNJ $USB $COF $BK $LLY @ http://t.co/n4QZIDxy7w
31 Oct 14 03:01:06
Weekly Dow #Stocks Trend $V $PG $PFE $JNJ $AXP $NKE $HD $MCD $JPM $MMM $UNH $TRV $GS $VZ $CSCO $BA $UTX $DIS @ http://t.co/TvzJfd0RGT
31 Oct 14 02:55:52
Pfizer $PFE #stock #investing: Although revenue fell in the third quarter, company managed to raise it's earn... http://t.co/OiHbuGEU4R
FinSentS SP500
31 Oct 14 00:23:47
$PFE:US Traders Sell Pfizer on Strength on Insider Selling (PFE) #PFIZER INC http://t.co/sOnR758dLD #SP500
30 Oct 14 23:30:09
Partner Jet $PJT.V is up 183% this week after Q3 release with more gains coming. Find out why: http://t.co/MEpEjkCm4H $PFE $P $CSX
Stock Signaling
30 Oct 14 21:01:36
Movers and Shakers: Making Range Advances: $ALU $BBY $GNC $TASR $CTRX $APD $AKAM $V $PRXL $BIDU $KEG $SPN $O $PFE $NM http://t.co/Vtx6dLy0Nw
30 Oct 14 20:38:08
Hottest in Twitter About $PFE (Pfizer Inc symbol PFE) on 10/31/2014 http://t.co/APVXstsNuf
30 Oct 14 19:48:21
Traders Sell Pfizer on Strength on Insider Selling $PFE http://t.co/3Iw4HQBdbw
US Banking News
30 Oct 14 19:42:11
Traders Sell Pfizer on Strength on Insider Selling $PFE http://t.co/bIG06kGhtZ
30 Oct 14 18:46:56
Partner Jet $PJT.V is up 183% this week after Q3 release with much more room to increase. Find out why: http://t.co/MEpEjkCm4H $MU $GSS $PFE
Alpha Maven
30 Oct 14 17:08:46
RT @pharmalot: Pharmalot.. Pharmalittle.. Good Morning.. lots of coffee & lots of headlines.. http://t.co/pPwXHIwESe #pharma $GILD $SNY $ES…
Sleek Money
30 Oct 14 16:49:57
Insider Selling: Anthony J. Maddaluna Sells 2,425 Shares of Pfizer Stock $PFE http://t.co/qxmTgXEqro
US Banking News
30 Oct 14 16:36:11
Pfizer EVP Anthony J. Maddaluna Unloads 2,425 Shares $PFE http://t.co/HFLPi9mvLs
30 Oct 14 16:01:41
S&P100 #Stocks Trend $V $MA $BMY $EXC $GILD $AEP $LLY $DOW $ABT $AMGN $LMT $RTN $ALL $JNJ $ACN $MET $PFE $HD @ http://t.co/n4QZIDxy7w
30 Oct 14 16:01:08
Dow #Stocks Trend $V $JNJ $PFE $HD $NKE $MCD $PG $AXP $JPM $UNH $MMM $TRV $BA $GS $VZ $CSCO $DIS $UTX $CVX $CAT @ http://t.co/TvzJfd0RGT
30 Oct 14 15:28:30
$PFE ALERT: New Pfizer SEC Filing From our Stock News Alerts App
30 Oct 14 15:28:14
$PFE - Statement of Changes in Beneficial Ownership (4) http://t.co/jQRHOWCH9J
30 Oct 14 15:28:12
$PFE - Statement of Changes in Beneficial Ownership (4) http://t.co/FKR1OCR1Ez
Solo traders
30 Oct 14 15:28:11
$PFE - Statement of Changes in Beneficial Ownership (4) http://t.co/U3PpBp80js
Market Newswire
30 Oct 14 14:32:21
Pfizer's Trumenba Gains Accelerated Approval in the U.S. - October 30, 2014 - http://t.co/Ob2WHgEwYX $PFE #wallstreet #finance #investing
Dee Du
30 Oct 14 14:11:28
@cvpayne Is it a good time to buy $GILD $CELG $PFE.... $MSFT?
Mayur Kherdikar
30 Oct 14 13:23:33
1st meningitis vaccine approved by USFDA. $PFE beats $NVS http://t.co/kCv4g5E4GH
30 Oct 14 13:22:49
Big winners drugs $MYL $TEVA and $PFE; big losers energy services $WMB $WFT
30 Oct 14 13:05:33
RT @JNapodano: My Zacks report on the Fish Oil market and new name $MTNB >> http://t.co/XSw4BeTEZk >> Also info on $AMRN $AZN $GSK $PFE $AB…
carl s
30 Oct 14 11:28:03
RT @biogemfinder: $ARNA $PFE $OREX $VVUS BelPhen doubles efficacy without side effects. Much better alternative to Qsymia or Contrave. htt…
30 Oct 14 10:40:59
http://t.co/hjgLwIcNgz leahanne: $PFE Pfizer Inc (PFE) 29.82 +0.33 (+1.12%) $UNG: leahanne http://t.co/HvEIfxyPff http://t.co/hjgLwIcNgz
Investors Hangout
30 Oct 14 10:40:08
leahanne: $PFE Pfizer Inc (PFE) 29.82 +0.33 (+1.12%) $UNG http://t.co/Zix0WpdFLL
Investors Hangout
30 Oct 14 10:40:07
leahanne: $PFE Pfizer Inc (PFE) 29.82 +0.33 (+1.12%) $UNG http://t.co/mm9qZiHPey
30 Oct 14 10:20:54
$PFE Pfizer Inc (PFE) 29.82 +0.33 (+1.12%) $UNG $GILD $SBUX http://t.co/bdwqlxZQJZ
By  +Follow July 30, 2013 8:52AM



blog comments powered by Disqus

About us

Equities.com is the most advanced interactive online social ecosystem for the financial industry, serving as a resource center and next-generation communication platform that connects self-directed investors with public issuers, market experts, and professional service providers and vendors. Registered members can leverage our exclusive proprietary research tools such as the Small-Cap Stars, which outperformed 90% of all small-cap mutual funds, and robust do-it-yourself E.V.A. research reports. The Equities.com Issuer Dashboard is the ideal tool to communicate and manage investor awareness campaigns to the investment community, as well as to access valuable resources to help your company grow.

Market Data powered by QuoteMedia.
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Terms of Use.